Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy

Inclusion Criteria: * 1: All patients provided voluntary, written informed consent prior to any study procedures. 2: Aged 18 years or older, both male and female. 3: Patients with clinically or pathologically confirmed Barcelona Clinic Liver Cancer (BCLC) stage B or C hepatocellular carcinoma, who are deemed eligible for hepatic arterial infusion chemotherapy (HAIC) combined with targeted and immunotherapy as assessed by the clinician. 4: No prior systemic antitumor therapy. 5: At least one intrahepatic evaluable lesion is present, with the intrahepatic lesion constituting the primary tumor burden. (According to RECIST v1.1 criteria, the measurable lesion must have a long diameter \>= 10 mm on spiral CT scan, or enlarged lymph nodes must have a short diameter \>= 15 mm.); 6: Child-Pugh score \<= 7 (Rated as Child-Pugh class A or B); 7: Able to swallow tablets normally; 8: ECOG performance status: 0-1; 9: Patients' psychological status and laboratory test indicators can be comprehensively documented at baseline and during the treatment period; 10: All patients have no history of other psychiatric disorders. Exclusion Criteria: 1\. Presence of any active autoimmune disease or history of autoimmune diseases (including, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; patients with vitiligo; childhood asthma that has completely resolved in adulthood …